EDCTP Call: Strategic action for overcoming drug resistance in malaria (deadline: 30th Oct 2018)

The European & Developing Countries Clinical Trials Partnership (EDCTP) wishes to support one large-scale strategic action (clinical research activities) that is part of a bigger portfolio of clinical trials with the capacity to develop new and diverse antimalarial drugs, including combination therapies that may be used for treatment or chemoprevention of malaria in sub-Saharan Africa.

Background

Current treatment of malaria is highly dependent on artemisinin-based combination therapies (ACT), but emerging resistance has highlighted the need to develop a broader portfolio of antimalarial drugs, including new or repurposed non-ACT drugs for chemoprevention and treatment as well as long-acting products with transmission blocking potential. 

Objectives

The action should have the potential to achieve maximum impact in the field and to make a significant contribution to the objectives of the EDCTP2 programme, and in particular:

  • contribute towards combatting drug resistance through development of new or improved antimalarial products
  • lead to the advancement of new drugs and/or drug combinations, with the aim of registration of new drug(s) and/or drug combinations for treatment and prevention of malaria in sub-Saharan Africa and globally
  • contribute to the reduction of malaria mortality and morbidity in sub-Saharan Africa, particularly in pregnant women, infants and children and
  • thus contribute to achieving SDG 3 ‘Ensure healthy lives and promote well-being for all at all ages’.

Eligibility

Consortia comprising a minimum of three independent legal entities are eligible to apply. Two of the legal entities shall be established in two different European Partner States and one of the legal entities must be established in a sub-Saharan African country.

Level of funding

Call budget: up to €22 million; with match funding for the grant expected from other funders. Proposals that leverage major relevant financial contributions from funders other than the EDCTP Association will be considered to have a higher impact.

For further details regarding the scope of this call, eligible countries of origin and submission guidelines, please see the EDCTP website.